3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione | 42285-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
• 英文别名: 3-(4-Chlorphenyl) toxoflavin；3-p-Chlorphenyl-toxoflavin；3-(4-Chloro-phenyl)-1,6-dimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione；3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
• CAS: 42285-61-0
• 化学式: C₁₃H₁₀ClN₅O₂
• 分子量: 303.708
• InChiKey: UCEGDYDPOSBUTP-UHFFFAOYSA-N

物化性质

• 熔点：
  227 °C(Solv: ethanol (64-17-5))
• 沸点：
  404.9±47.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  77.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 以40%的产率得到3-(4-chlorophenyl)-1,5-dimethyl-1H-imidazo[4,5-e][1,2,4]triazin-6(5H)-one
  参考文献：
  名称：

  转化黄素和Reumycins（7-Azapteridines）合成6-氮杂嘌呤及其细胞毒性

  摘要：

  本文介绍了一种可靠且简便的合成6-氮杂uri啶酮，1,5-二甲基-1 H-咪唑并[4,5- e ] [1,2,4]三嗪-6（5 H）-ones和5-甲基-5 H-咪唑并[4,5- e ] [1,2,4]三嗪-6（7 H）-一，通过在10-70°C或回流下用10％氢氧化钠或乙醇乙醇溶液处理毒素黄素和瑞霉素，然后通过空气脱羧和氧化以及苯甲酸类型重排。此外，将产生的6-氮杂嘌呤在10％乙醇氢氧化钠中加热，得到具有1-甲基脲的相应的1-甲基-5,6-二氧代-1,4,5,6-四氢-1,2,4-三嗪。还研究了6-氮杂嘌呤类药物对CCRF-HSB-2（人类T细胞急性淋巴母细胞性白血病）和KB（人类口腔表皮样癌）细胞系的抗肿瘤活性，其中某些化合物显示出预期的抗肿瘤活性。

  DOI：

  10.1071/ch14425
• 作为产物：
  描述：

  3-甲基-6-(1-甲基肼基)-2,4(1H,3H)-嘧啶二酮 在 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 生成 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
  参考文献：
  名称：

  Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of β-catenin/TCF transcription

  摘要：

  Nearly all colorectal cancers (CRCs) and varied subsets of other cancers have somatic mutations leading to beta-catenin stabilization and increased beta-catenin/TCF transcriptional activity. Inhibition of stabilized beta-catenin in CRC cell lines arrests their growth and highlights the potential of this mechanism for novel cancer therapeutics. We have pursued efforts to develop small molecules that inhibit beta-catenin/TCF transcriptional activity. We used xanthothricin, a known beta-catenin/TCF antagonist of microbial origin, as a lead compound to synthesize related analogues with drug-like features such as low molecular weight and good metabolic stability. We studied a panel of six candidate Wnt/beta-catenin/Tcf-regulated genes and found that two of them (Axin2, Lgr5) were reproducibly activated (9-10 fold) in rat intestinal epithelial cells (IEC-6) following beta-catenin stabilization by Wnt-3a ligand treatment. Two previously reported beta-catenin/TCF antagonists (calphostin C, xanthothricin) and XAV939 (tankyrase antagonist) inhibited Wnt-activated genes in a dose-dependent fashion. We found that four of our compounds also potently inhibited Wnt-mediated activation in the panel of target genes. We investigated the mechanism of action for one of these (8c) and demonstrated these novel small molecules inhibit beta-catenin transcriptional activity by degrading beta-catenin via a proteasome-dependent, but GSK3 beta-, APC-, AXIN2- and beta TrCP-independent, pathway. The data indicate the compounds act at the level of beta-catenin to inhibit Wnt/beta-catenin/TCF function and highlight a robust strategy for assessing the activity of beta-catenin/TCF antagonists. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.111

文献信息

• Microwave-assisted synthesis of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione libraries: derivatives of toxoflavin
  作者：Nick Todorovic、Andrew Giacomelli、John A. Hassell、Christopher S. Frampton、Alfredo Capretta

  DOI：10.1016/j.tetlet.2010.09.044

  日期：2010.11

  The parallel synthesis of a library of toxoflavin derivatives is described. The microwave-assisted approach involves the de novo generation of the heterocyclic scaffold and allows for facile introduction of a variety of fragments.

  描述了一种平行合成的毒素类黄素衍生物的文库。微波辅助方法涉及从头产生杂环支架，并允许容易地引入各种片段。
• The Facile Synthesis of 6-Azapurines by Transformation of Toxoflavins (7-Azapteridines)
  作者：Tomohisa Nagamatsu、Jun Ma、Fumio Yoneda

  DOI：10.3987/com-08-s(f)111

  日期：——

  - This paper describes a reliable and facile synthesis of 6-azapurines (1,5-dimethyl-1H-imidazo[4,5-e][1,2,4]triazin-6(5H)-ones) by treatment of toxoflavins (7-azapteridines) with 10% aqueous sodium hydroxide at 5-25 °C along with a benzilic acid type rearrangement, followed by decarboxylation and oxidation by air. Furthermore, heating the 6-azapurines in 10% ethanolic sodium hydroxides afforded the

  - 本文描述了通过处理毒黄素可靠而简便地合成 6-氮杂嘌呤 (1,5-dimethyl-1H-imidazo[4,5-e][1,2,4]triazin-6(5H)-ones) (7-azapteridines) 与 10% 氢氧化钠水溶液在 5-25 °C 下进行苯甲酸型重排，然后通过空气进行脱羧和氧化。此外，在 10% 乙醇氢氧化钠中加热 6-氮杂嘌呤，得到相应的 1,2,4-三嗪-5,6(1H,4H)-二酮，这是由 6-氮杂嘌呤的咪唑环裂变引起的。
• Toxoflavins and Deazaflavins as the First Reported Selective Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase II
  作者：Ali Raoof、Paul Depledge、Niall M. Hamilton、Nicola S. Hamilton、James R. Hitchin、Gemma V. Hopkins、Allan M. Jordan、Laura A. Maguire、Alison E. McGonagle、Daniel P. Mould、Mathew Rushbrooke、Helen F. Small、Kate M. Smith、Graeme J. Thomson、Fabrice Turlais、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1021/jm400568p

  日期：2013.8.22

  The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAP.) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.
• Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same
  申请人：Showalter H.D. H.

  公开号：US20110166144A1

  公开（公告）日：2011-07-07

  The present disclosure is directed to pyrimidotriazinediones and pyrimidopyrimidinediones having a formula (I), (II), or (III), or a mixture or pharmaceutically acceptable salt or hydrate thereof, and to methods of treating cancer comprising administering the same.
• COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION
  申请人：Wong Chi-Huey

  公开号：US20130158037A1

  公开（公告）日：2013-06-20

  The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus , and thus are useful in the treatment of tuberculosis infection and associated conditions. The present invention is further directed to in vitro- and in vzivo-based methods of inhibiting Lpd and/or PDH activity. In certain embodiments, these methods are useful in inhibiting Lpd and/or PDH activity key to a pathogen's survival.